Test Your Hypertrophic Cardiomyopathy Clinical Knowledge
Reviewed by: HU Medical Review Board | Last reviewed: July 2026 | Last updated: July 2026
Management of hypertrophic cardiomyopathy (HCM) has moved quickly – from how obstruction is provoked and confirmed, through sudden-death risk stratification, to an expanding pharmacologic toolkit. These 5 questions assess current, guideline-aligned clinical knowledge across the disease spectrum.
Clinical Challenge
A symptomatic patient with HCM has no significant left ventricular outflow tract (LVOT) gradient on resting echocardiography. Which approach best unmasks a dynamic gradient?
Clinical Challenge
In a patient with symptomatic obstructive HCM, which agent is most likely to worsen the dynamic outflow tract gradient?
Clinical Challenge
Cardiac myosin inhibitors improve symptoms in obstructive HCM by which mechanism, and what monitoring do they require?
Clinical Challenge
A 24-year-old with HCM and preserved systolic function reports one episode of exertional loss of consciousness that is not explained by neurocardiogenic or outflow causes. Which finding most supports discussing an implantable cardioverter-defibrillator?
Clinical Challenge
A patient is newly diagnosed with sarcomeric HCM. What is the recommended approach for first-degree relatives?